Piper Sandler Maintains Overweight on CME Gr, Lowers Price Target to $225
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Patrick Moley maintains an Overweight rating on CME Group (NASDAQ:CME) but lowers the price target from $235 to $225.
July 25, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on CME Group but lowers the price target from $235 to $225.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on CME's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100